FERROCHOLINATE ANHYDROUS

First approved in 1953

Details

Stereochemistry	ACHIRAL
Molecular Formula	C6H4O7.C5H14NO.Fe
Molecular Weight	348.108
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[Fe+3].C[N+](C)(C)CCO.[O-]C(=O)CC([O-])(CC([O-])=O)C([O-])=O

InChI

InChIKey=YJBFEDKRBVBHSN-UHFFFAOYSA-K

InChI=1S/C6H7O7.C5H14NO.Fe/c7-3(8)1-6(13,5(11)12)2-4(9)10;1-6(2,3)4-5-7;/h1-2H2,(H,7,8)(H,9,10)(H,11,12);7H,4-5H2,1-3H3;/q-1;+1;+3/p-3

HIDE SMILES / InChI

Molecular Formula	C6H5O7
Molecular Weight	189.0997
Charge	-3
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C5H13NO
Molecular Weight	103.1628
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	Fe
Molecular Weight	55.845
Charge	3
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.aemps.gob.es/cima/pdfs/es/ft/54556/54556_ft.pdf
Curator's Comment: description was created based on several sources, including: http://www.druginfosys.com/drug.aspx?drugcode=1316&type=1 | http://www.vademecum.es/medicamento-podertonic+adultos_3181

Ferrocholinate is a chelate prepared by reacting equal quantities of freshly precipitated ferric chloride with choline dihydrogen citrate. Ferrocholinate is used as a source of iron in iron deficiency anemia. Ferrocholinate absorption is increased by simultaneous administration of ascorbic acid. Absorption reduced by antacids, cholestyramine or proton pump inhibitors (omeprazole, pantoprazole, lansoprazole). The following adverse effects may occur: occasionally, gastrointestinal disorders (stomach pain, nausea, constipation or diarrhea) may appear, which usually disappear quickly after the dose is reduced or, if necessary, after treatment discontinuation. Darkness of stool: it is frequently observed during treatment and is safe for the patient. Allergic reactions may occur, also.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
hemoglobin metabolic process 2 Target ID: GO:0020027 Sources: https://www.aemps.gob.es/cima/pdfs/es/ft/54556/54556_ft.pdf	Modulator 828

Conditions

Condition	Modality	Highest Phase	Product
Iron deficiency anemia 56 Sources: http://www.druginfosys.com/drug.aspx?drugcode=1316&type=1	Primary	Approved 8429	FERROLIP Approved Use Ferrocholinate is primarily indicated in conditions like iron deficiency anaemia. Launch Date 1960
Chronic bleeding 2 Sources: http://www.vademecum.es/medicamento-podertonic+adultos_3181	Primary	Approved 8429	FERROLIP Approved Use Treatment of iron deficiency states and iron deficiency anemia in adults and children, for deficient iron absorption, chronic bleeding or in situations where there is an increase of iron demands such as pregnancy or breastfeeding. Launch Date 1960
Iron absorption deficiency 2 Sources: https://www.aemps.gob.es/cima/pdfs/es/ft/54556/54556_ft.pdf	Primary	Approved 8429	FERROLIP Approved Use Treatment of iron deficiency states and iron deficiency anemia in adults and children, for deficient iron absorption, chronic bleeding or in situations where there is an increase of iron demands such as pregnancy or breastfeeding. Launch Date 1960

Sourcing

Vendor/Aggregator	ID	URL
3B Scientific (Wuhan) Corp	3B3-054251	http://www.3bsc.com/index/pro_info.php?id=92722
BOC Sciences	65228-13-9	https://www.bocsci.com/ferric-choline-citrate-cas-65228-13-9-item-205804.html
PubChem	76966607	https://pubchem.ncbi.nlm.nih.gov/compound/76966607

PubMed

Title	Date	PubMed

Patents

Sample Use Guides

In Vivo Use Guide

1 tablet (100 mg) daily Adults daily dose is equivalent to 112.6 mg Fe3. Take this medication preferably a few hours before meals. Duration of treatment depends on nature and severity of iron deficiency.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Sat Dec 16 01:36:27 GMT 2023` Edited by `admin` on `Sat Dec 16 01:36:27 GMT 2023`
Record UNII	0W21KB56NS
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

FERROCHOLINATE ANHYDROUS

Common Name

English

ETHANAMINIUM, 2-HYDROXY-N,N,N-TRIMETHYL-, (OC-6-44)-(2-(HYDROXY-.KAPPA.O)-1,2,3-PROPANETRICARBOXYLATO(4-)-.KAPPA.O1,.KAPPA.O2)FERRATE(1-) (1:1)

Common Name

English

Code System Code Type Description

PUBCHEM

76966607

Created by admin on Sat Dec 16 01:36:28 GMT 2023 , Edited by admin on Sat Dec 16 01:36:28 GMT 2023

PRIMARY

FDA UNII

0W21KB56NS

Created by admin on Sat Dec 16 01:36:28 GMT 2023 , Edited by admin on Sat Dec 16 01:36:28 GMT 2023

PRIMARY

Related Record Type Details


					XF417D3PSL

ANHYDROUS CITRIC ACID

PARENT -> SALT/SOLVATE


					LWI5ZJ8WVL

FERROCHOLINATE

SOLVATE->ANHYDROUS


					N91BDP6H0X

CHOLINE

PARENT -> SALT/SOLVATE


					91O4LML611

FERRIC CATION

PARENT -> SALT/SOLVATE

Details

SMILES

InChI

DescriptionSources: https://www.aemps.gob.es/cima/pdfs/es/ft/54556/54556_ft.pdfCurator's Comment: description was created based on several sources, including: http://www.druginfosys.com/drug.aspx?drugcode=1316&type=1 | http://www.vademecum.es/medicamento-podertonic+adultos_3181

Originator

Approval Year

Targets

Conditions

Approved Use

Launch Date

Approved Use

Launch Date

Approved Use

Launch Date

Sourcing

PubMed

Patents

Sample Use Guides

Description
Sources: https://www.aemps.gob.es/cima/pdfs/es/ft/54556/54556_ft.pdf
Curator's Comment: description was created based on several sources, including: http://www.druginfosys.com/drug.aspx?drugcode=1316&type=1 | http://www.vademecum.es/medicamento-podertonic+adultos_3181